Sumner Glen, Salehian Omid, Yi Qilong, Healey Jeff, Mathew James, Al-Merri Khalid, Al-Nemer Khaled, Mann J F E, Dagenais Gilles, Lonn Eva
Department of Medicine, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada.
J Cardiovasc Electrophysiol. 2009 Jul;20(7):781-7. doi: 10.1111/j.1540-8167.2009.01440.x. Epub 2009 Feb 27.
The prognostic significance of left and right bundle branch block (LBBB and RRBB) in patients with chronic stable cardiovascular (CV) disease is not well characterized and was evaluated in the Heart Outcomes Prevention Evaluation (HOPE) study cohort.
Observational analysis of data prospectively collected in the HOPE trial.
HOPE was a multicenter, international trial, which evaluated ramipril and vitamin E in 9,541 patients aged > or = 55 years with CV disease or diabetes with > or = 1 CV risk factor(s) but without heart failure (HF) or known left ventricular systolic dysfunction. Follow-up extended for a median of 4.5 years. Electrocardiograms were obtained at baseline in all study participants and were read centrally.
Major CV events (defined as CV death, myocardial infarction, or stroke), heart failure, CV death, all-cause death, and sudden death.
Baseline LBBB was present in 246 (2.6%) patients and was associated with increased risk for major CV events (HR = 1.54; 95% CI, 1.18-2.02), CV death (HR 2.29; 95% CI, 1.63-3.20), heart failure (HR 2.99; 95% CI, 2.31-3.87), sudden death (HR 3.17; 95% CI, 2.13-4.73), and all-cause death (HR = 2.10; 95% CI, 1.59-2.77). In multivariate models, LBBB remained an independent predictor of heart failure, sudden death, CV death, and all-cause death (P < or = 0.002 for all). Baseline RBBB was present in 428 (4.5%) of patients and was not associated with increased CV risk.
In patients with stable chronic CV disease, LBBB but not RBBB is an independent predictor of heart failure, sudden death, CV death, and all-cause death.
慢性稳定型心血管疾病患者左、右束支传导阻滞(LBBB和RBBB)的预后意义尚未得到充分阐明,本研究在心脏转归预防评估(HOPE)研究队列中对其进行了评估。
对HOPE试验前瞻性收集的数据进行观察性分析。
HOPE是一项多中心国际试验,在9541例年龄≥55岁、患有心血管疾病或糖尿病且有≥1个心血管危险因素、但无心力衰竭(HF)或已知左心室收缩功能障碍的患者中评估雷米普利和维生素E。随访时间中位数为4.5年。所有研究参与者均在基线时进行心电图检查,并由中心实验室进行解读。
主要心血管事件(定义为心血管死亡、心肌梗死或卒中)、心力衰竭、心血管死亡、全因死亡和心源性猝死。
246例(2.6%)患者存在基线LBBB,其与主要心血管事件风险增加相关(HR = 1.54;95%CI,1.18 - 2.02)、心血管死亡(HR 2.29;95%CI,1.63 - 3.20)、心力衰竭(HR 2.99;95%CI,2.31 - 3.87)、心源性猝死(HR 3.17;95%CI,2.13 - 4.73)和全因死亡(HR = 2.10;95%CI,1.59 - 2.77)。在多变量模型中,LBBB仍然是心力衰竭、心源性猝死、心血管死亡和全因死亡的独立预测因素(所有P≤0.002)。428例(4.5%)患者存在基线RBBB,其与心血管风险增加无关。
在稳定的慢性心血管疾病患者中,LBBB而非RBBB是心力衰竭、心源性猝死、心血管死亡和全因死亡的独立预测因素。